Chugai Pharmaceutical Co., Ltd. (CHGCF)

Market Cap	76.76B
Revenue (ttm)	7.45B
Net Income (ttm)	2.46B
Shares Out	n/a
EPS (ttm)	1.50
PE Ratio	31.16
Forward PE	n/a
Dividend	0.62 (1.41%)
Ex-Dividend Date	Dec 27, 2024

Volume	621
Average Volume	4,333
Open	43.69
Previous Close	47.38
Day's Range	43.69 - 43.69
52-Week Range	29.04 - 50.31
Beta	0.54
RSI	47.31
Earnings Date	Apr 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCF

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY